Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide).…
Smithers Avanza, a contract research organization supporting the pharmaceutical industry, announced that its Bioanalytical Services Division has completed the second expansion…
Immunomic Therapeutics negotiated an exclusive license to Annias Immunotherapeutics’ platform covering technology for targeting cytomegalovirus (CMV) antigens in cancer.…